Therefore, considering the prominent role of mitochondria in the onset of melanoma therapeutic resistance [302], mTOR signaling seems to be involved in the regulation of this process at the switch between sensitivity and resistance to BRAFi/MEKi. This evidence concerns the gene MTOR and melanoma.